Announcement PDF 0 Commercialising a New Class of Synthetic Anti-Infectives ASX:RCE | FSE:R9Q June 2026 recce.com.au Disclaimer This presentation is dated June 2026 and has been prepared by Recce Pharmaceuticals Limited (ACN 124 849 065) (“Recce” or the “Company”) in connection with the institutional placement of new fully paid ordinary shares (“New Shares”) in the Company (the “Offer”). By receiving this presentation, you are agreeing to the following restrictions and limitations. Summary Information This presentation contains summary information about Recce and its subsidiaries, and their activities current as at the date of the presentation. The information in this presentation is general in nature and does not purport to be complete, nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Recce. The historical information in this presentation is, or is based upon, information that has been released to the ASX. This presentation should be read in conjunction with Recce’s other periodic and continuous disclosure announcements lodged with ASX, which are available at www.asx.com.au. The information contained in this presentation is provided as at the date of this presentation (unless otherwise stated) and is subject to change without notice. Recce is not obligated to update it or correct it. Not An Offer This presentation is for information purposes only and is not a prospectus, product disclosure statement or other disclosure or offer document under Australian law or under any other law. It will not be lodged with the Australian Securities and Investments Commission (“ASIC”) or any other local or foreign regulator or law. This presentation is not an offer or an invitation to acquire the New Shares or any other financial products in any jurisdiction in which, or to any person to whom, it would be unlawful to make such an offer or invitation. The New Shares will only be offered or issued in Australia to investors to whom offers and issues of New Shares may lawfully be made in Australia without the need for disclosure to investors under Chapter 6D of the Corporations Act 2001 (Cth). The distribution of this presentation and the offer of New Shares is restricted in jurisdictions outside Australia. You should read the restrictions set out in the section of this presentation headed “International Selling Restrictions” for more information. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. By accepting this presentation, you represent and warrant that you are entitled to receive this presentation in accordance with those restrictions and agree to be bound by them and any other limitations contained in this presentation. In particular, this presentation may not be released to US wire services or distributed in the United States. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or any other jurisdiction in which such an offer would be illegal. The New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Important Notice and Disclaimer 1 recce.com.au Important Notice and Disclaimer Not Financial Product Advice This presentation does not, and does not purport to, contain all the information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) or any recommendation to acquire New Shares, and must not be relied upon as such and does not and will not form any part of any contract or commitment for the acquisition of New Shares. Any decision to buy or sell securities or other products should be made only after seeking appropriate financial advice. This presentation is of a general nature and does not take into consideration the individual investment objectives, financial situation or particular needs of any particular investor. Before making any investment decision, you should consider the appropriateness of the information having regard to your own objectives, financial situation and particular needs, and seek appropriate professional advice from your stockbroker, solicitor, accountant or other independent and qualified professional adviser. Each recipient of this presentation should make their own enquiries and investigations regarding all information included in it, including the assumptions, uncertainties and contingencies which may affect Recce’s future operations, and the impact that future outcomes may have on Recce and its controlled entities (the “Group”). For more information about Recce, visit the website at www.recce.com.au. Investment Risk An investment in Recce is subject to both known and unknown risks, some of which are beyond the control of Recce and its directors. Recce does not guarantee any particular rate of return or the performance of Recce nor does it guarantee any particular tax treatment. You should have regard to the risk factors outlined in the section of this presentation headed “Key Risks” when making your investment decision. Cooling off rights do not apply to the acquisition of New Shares. Financial Data Unless otherwise stated, or as the context requires, all figures in this presentation are in Australian dollars. Certain financial information and measures included in this presentation are (i) “non-IFRS financial information” under ASIC Regulatory Guide 230: “Disclosing non-IFRS financial information” and (ii) “non-GAAP financial measures” under Regulation G issued by the U.S. Securities and Exchange Commission (“SEC”) and are not recognised under Australian Accounting Standards (“AAS”) and International Financial Reporting Standards (“IFRS”). Therefore, the non-IFRS/non-GAAP financial information may not be comparable to similarly titled measures presented by other entities and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. Recce believes these non-IFRS/non-GAAP financial measures provide useful information to investors in measuring the financial performance and condition of its business. However, investors should note that the non-IFRS/non-GAAP financial measures do not have standardised meanings prescribed by AAS or IFRS. Investors are therefore cautioned to not place undue reliance on any non-IFRS/non- GAAP financial information included in this presentation. This presentation includes certain pro forma financial information (to reflect the impact of the equity raising). The pro forma historical financial information provided in this presentation is for illustrative purposes only and is not represented as being indicative of Recce’s views on its future financial position and/or performance. The pro forma historical financial information has been prepared by Recce in accordance with the measurement and recognition principles, but not the disclosure requirements, prescribed by the AAS. In addition, the pro forma financial information in this presentation does not purport to be in compliance with Article 11 of Regulation S-X of the rules and regulations of SEC. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the precise calculation of these figures may differ from the figures set out in this presentation. 2 recce.com.au Important Notice and Disclaimer Past Performance No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Recce or its directors, or any of their employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. In particular, no representation or warranty, express or implied is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of any forecasts, projections, prospects or returns contained in this presentation, nor is any obligation assumed to update such information. Such forecasts, prospects or returns are by their nature subject to significant uncertainties and contingencies. Past performance and pro forma historical financial information is given for illustrative purposes only. It should not be relied on and is not an indication of future performance, including future share prices. For further details on historical information relating to the Group, you should see past announcements that Recce has released to ASX. Market Data Certain market and industry data used in this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Recce nor its representatives or its advisers have independently verified any such market or industry data provided by third parties or industry or general publications. Future Performance and Forward-Looking Statements This presentation contains certain “forward-looking statements”. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “continue”, “should”, “could”, “predict”, “objectives”, “outlook”, “guidance” or other similar words, statements regarding certain plans, strategies and objectives of management, indications of and guidance or outlook on production estimates and targets, statements about current and future plans regarding exploration, statements about the outcome and effect of the proposed Placement, statements about other opportunities, and expected future earnings and financial earnings and performance. Forward looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks, uncertainties and other factors, which are outside the control of Recce and any of its officers, employees, agents or associates. This also includes statements about market and industry trends, which are based on interpretations of current market conditions. Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Forward-looking statements may be affected by a range of variables, including but not limited to the risks described in this presentation under the section headed "Key Risks". Investors are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility and uncertainty. Forward- looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. These statements may assume the success of Recce’s business strategies, the success of which may not be realised within the period for which the forward-looking statement may have been prepared, or at all. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this presentation. Except as required by law or regulation (including the ASX Listing Rules), none of Recce, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. 3 recce.com.au Executive Summary Commercialising a new class of synthetic anti-infectives Overview of Recce Pharmaceuticals • Recce Pharmaceuticals Limited (Recce or the Company) is developing a New Class of Synthetic Anti-Infectives with the potential to overcome antibiotic-resistant superbugs – the challenge of all antibiotics to date • Lead drug candidate RECCE® 327 (R327) is recognized by the World Health Organization as one of the world’s most clinically advanced new classes of antibiotics - the first in over 40 years • Recce has a promising pipeline of Phase 2 / 3 clinical trials across multiple key geographies with significant revenue catalysts over the next 6 to 12 months Registrational Phase 3 trial catalyst for near term revenue • Phase 3 Registrational clinical trial for Diabetic Foot Infections (DFI) is underway in Indonesia, with five clinical study sites activated and a target enrolment of 310 patients; Recce has been awarded expedited regulatory review status to fast-track progression and review • Recce expects to receive an interim data readout of 155 patients, targeted for Q3 CY2026 - an approvable dataset that will be submitted to Indonesia's Badan POM for commercial approval, representing the first near-term commercialisation milestone • The Phase 3 trial is underpinned by a Memorandum of Understanding with leading biomedical company PT Etana Biotechnologies (Etana), providing established in-country infrastructure and regulatory expertise • Commercial approval in Indonesia opens access to 10 ASEAN member states, covering a population of 680 million, with further geographic expansion opportunities beyond the region available • Significant bilateral initiative supported by Australian and Indonesian Governments Non-binding Term Sheet with leading Middle Eastern pharmaceuticals company • Recce has signed a non-binding term sheet with a leading Middle Eastern pharmaceutical company for a 10 year exclusive multi-country licensing agreement for the licensing of R327G through the MENA region • The agreement is expected to include an upfront signing fee, together with milestone payments totalling up to USD $3.5 million (~AUD $5.0 million), 30% of the net selling price and an additional 6% annual royalty on net sales above USD $50 million — at a proposed selling price of USD $1,500 per treatment • R327G addresses a critical unmet need across the MENA region — home to 84 million people living with diabetes and a prevalence rate of 23.1% in Saudi Arabia alone Capital raising to strengthen balance sheet and progress commercialisation initiatives • Up to ~A$4.0 million institutional placement (Placement), and ~$4.0 million SPP to raise up to a total of $8.0 million (the Offer) • Funds raised under the Offer will be used to position the Company to expand into the Middle East and North Africa (MENA) region following the signing of the commercial licensing agreement and fund Recce through to completion of the Phase 3 Registrational clinical trial in Indonesia • Offer price of A$0.40 per new share (Offer Price), which represents a discount of: ‒ 13.0% to Recce’s last closing price on 23 June 2026 of A$0.46; ‒ 19.4% to the 10-day volume weighted average price (VWAP) of A$0.497 per share as at 23 June 2026 • Post completion, Recce will have available funding of up to ~$29.5 million*. *Includes Offer proceeds (before costs) and A$1.7 million of cash as at 31 March 2026 4 Recce Pharmaceuticals Limited (ASX:RCE) | Equity Raising Presentation | 5 5 Company Overview Recce Pharmaceuticals – Company Overview RECCE® 327 granted Qualified Infectious Disease Product (QIDP) Designation by U.S. Food and Drug Administration giving 10 years market exclusivity plus fast-track approval. RECCE® 327 added to World Health Organization’s List of Antibacterial Products in Clinical Development. 6 Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones Products address the global healthcare crisis of antibiotic resistance: working faster than traditional antibiotics and against multidrug resistant bacteria Patient dosing has commenced for Phase 3 clinical trial in Indonesia of lead asset RECCE® 327 Gel for the treatment of Diabetic Foot Infections – interim data readout expected Q3 CY2026 and commercialisation in 2027 Recce has signed a non-binding term sheet with a leading Middle Eastern pharmaceutical company for a 10 Year exclusive multi-country licensing agreement Multiple clinical indications and formulations addressing unmet medical needs Agreements with US Defense Burn Research Program and US Army Medical Research Institute of Infectious Diseases further support Recce's product potential recce.com.au The Advantages of a New Class of Antibiotics Recce is on-track to be the only global clinical stage company whose drug is shown to be efficacious against the full suite of ESKAPE pathogens Universal Mechanism of Action - does not succumb to resistance Unprecedented, broad-spectrum activity against Gram-positive and Gram-negative bacteria Extremely rapid onset of effect – measured in minutes as compared to hours for typical antibiotics Multiple formulations available – intravenous, topical liquid, topical gel and aerosol for inhalation or intranasal 7 © Australian Bureau of Statistics, GeoNames, Microsoft, Navinfo, Open Places, OpenStreetMap, Overture Maps Fundation, TomTom, Zenrin Powered by Bing Large Addressable Market 8 The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems US$5.8B Est. global DFI treatment market1 Source: (1) Grand View Research, Diabetic Foot Ulcer Treatment Market Size, 2025 (2) Grand View Research, Anti-Infective Agents Market Size, 2023 (3) Diabetes Atlas, International Diabetic Federation and Prof EM Yunir, Faculty of Medicines, University of Indonesia. (4) https://diabetesatlas.org/data-by-location/region/middle-east-and-north-africa/ (5) https://idf.org/about-diabetes/diabetes-facts-figures/ (6) The current burden of diabetic foot disease – PMC (7) https://doi.org/10.1016/j.heliyon.2024.e41263 INDONESIA MENA GLOBAL >20 million adults in Indonesia with diabetes3 >84 million adults in MENA region with diabetes4 >589 million adults globally with diabetes5 Est. global market opportunities in the anti-infectives market2 • For adults with diabetes, approximately one in three adults will develop a diabetic foot ulcer in their lifetime6 • In Indonesia, DFI’s are severe in 67.1% of hospitalised cases and result in amputation in 46.9% of patients7 US$135.4B recce.com.au Program Pipeline* driven by 1st approval in Diabetic Foot Infections 2026 2027 2028 2029 2030 R327 Topical R327 Topical R327 I.V. Program R327 Inhaled – Lung Infections Civil & Dept of War Programs Phase 3 Interim Data Readout - 155 patients Hospital-Acquired Pneumonia (HAP) Ventilator Associated Pneumonia (VAP) DFI/ABSSSI AUSTRALIA/USA Diabetic Foot Ulcer Infection GEL INDONESIA/ASEAN Burn Wound Infections USA Mechanism of Action (MoA) Peer Reviewed Publication MoA paper published Phase I/II Trials of R327 Nebuliser Preclinical Trials of R327 Nebuliser Registrational Trials of R327 Nebuliser Potential Phase II Trials of R327 IV Preclinical Trials of R327G with Department of War (DoW) Additional Registrational Clinical Trials and Data for AUS/US Approval Indo trial data used for global registration strategy R327G Registered in Australia/US File NDA Phase I Complete, safe and well tolerated *The information and forecasts presented reflect management’s current expectations as at the date of this presentation. These statements involve assumptions, including the availability of appropriate funding, and are subject to known and unknown risks and uncertainties. Actual outcomes may differ from those expressed or implied and the Company reserves the right to revise its plans, projections, and strategic priorities as circumstances change. Registrational Trials of R327G For Burn Wounds Phase 3 Interim Data Readout Positive Indonesian Phase 3 Clinical Trial data readouts, together with subsequent regulatory approval would support commencement of commercialisation activities in Indonesia, ASEAN and MENA R327G Registered in Indonesia R327G Registered in ASEAN Various indications and upcoming inflection points • Approval received from the Indonesian Drug and Food Regulation Authority, Badan POM, to initiate its Registrational Phase 3 clinical trial in Indonesia • ABSSSI includes postoperative infection, wound infections and diabetic foot infections Program Pipeline for 2026 • Completed pilot civil Phase II Burn Wound Infections Study; US$2M grant for Department of Defense pre-clinical pipeline in progress • Cooperative Research and Development Agreement signed with US Army Medical Research Institute of Infectious Diseases, to test R327 against biothreat pathogens in established in vitro models. 10 Unlocks MENA Diabetes Market • The MENA region has a diabetes prevalence of 17.6% with over 84 million people living with diabetes– in Saudi Arabia, 23.1% of the adult population have been diagnosed with diabetes • The non-binding Term Sheet coverage is across the KSA, GCC countries (UAE, Kuwait, Oman, Bahrain, Qatar), Iraq, Egypt, Algeria and Morocco Validation of Premium Pricing • Non-binding Term Sheet stipulates a proposed selling price of USD $1,500 per treatment or a price mutually agreed with the KSA regulatory authority • Recce expected to receive 30% of the Net Selling Price with an additional 6% annual royalty on net sales >USD$50 million/year Data Harmonisation from Indonesia • Successful data read outs in Indonesia together with subsequent regulatory approval would support commercialisation in Indonesia and may support similar regulatory approval and commercialisation in other ASEAN markets. • Pending positive Phase 3 clinical trial results from the ongoing Indonesian trial, no additional clinical trials are expected to be required to support a marketing authorisation application in Saudi Arabia Commercial Partnership with Leading Company • The partner is recognised as one of the leading pharmaceutical companies in the MENA region • With a strong sales portfolio of products across dermatology, endocrinology and infectious diseases and established market access throughout the region, the partner is well positioned to accelerate the adoption and distribution of R327G Middle Eastern Pharmaceutical Company Term Sheet 7 Recce has signed a non-binding term sheet with a leading Middle Eastern Pharmaceutical Company for a 10-year exclusive multi-country licensing agreement for the licensing of R327G through the MENA region     Non-binding term sheet is a positive step towards the potential commercialisation of R327G across one of the world's most significant diabetes markets Term Sheet Highlights recce.com.au Company Overview Capital Structure – June 2026 ASX & FSE Code RCE, R9Q Share Price AUD $0.460 3-Month Daily Average Daily Volume 96.05k Shares on Issue 289.18 million Unlisted Options (Avg $1.087) 24.17 million Market Capitalisation AUD $133.0 million Top 20 Shareholders 57% RCE Share Price and Volume Chart – 12 Months (price shown in AUD) Australian Government awarded up to AUD $85 million Advanced Overseas Finding across RCE infectious disease portfolio* Multiple clinical indications and formulations in Phase I and Phase II addressing unmet medical needs: Sepsis, UTI/Urosepsis, Burn Wounds and ABSSSI, including Diabetic Foot Infections Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Volume Close $ *The Advanced Finding is a binding, underwritten guarantee provided by the Australian Government, which affirms the Company’s R&D activities are of national interest and extends the 43.5% R&D rebate from locally, to cover those undertaken by the Company anywhere in the world for a period of three years. This finding does not constitute a grant, or an upfront payment of the amount awarded Proprietary first-in-class, broad- spectrum anti-infectives against bacteria I.V. and topical treatments advancing for UTI/Urosepsis and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) including DFI; and US Department of Defense Burn Wound Program and Indonesian clinical trials for topical treatments. 12 0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 $0.20 $0.30 $0.40 $0.50 $0.60 $0.70 $0.80 Jun 2025 Jul 2025 Aug 2025 Sep 2025 Oct 2025 Nov 2025 Dec 2025 Jan 2026 Feb 2026 Mar 2026 Apr 2026 May 2026 Board and Management Structure 13 Dr John Prendergast – Chairman BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) US-based, current Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) and Lead Director of Nighthawk Biosciences (NYSE: HHWK). With extensive experience in the international commercialisation of pharmaceutical technologies, Dr Prendergast has been responsible for the approval of three new drug applications and played a pivotal role in the successful sale of Vylessi® to Cosette Pharmaceuticals for USD $159 million in contingent, sales- based milestones, marking a significant achievement in the pharmaceutical landscape James Graham – Managing Director & Chief Executive Officer BCom (Entrepreneurship), GAICD Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He brings extensive experience in marketing, business development, and the commercialisation of early-stage technologies with global potential. With a proven track record of growing globally focused companies, Mr Graham has applied his expertise to Recce, including serving on its Board of Directors. He has participated in nearly every capital raise to date, demonstrating a strong commitment to expanding Recce’s commercial opportunities and clinical programs. Dr Alan Dunton – Chief Medical Advisor & Non-Executive Director BSc (BioChem) Hons, M.D. (NYU) US based, Director of Palatin Technologies. Over three decades of senior pharmaceutical experience incl. President and MD of Janssen Research Foundation (Johnson & Johnson). Dr Dunton has advanced a number of blockbuster antibiotics through regulatory review and commercialisation at Fortune 500 companies including Roche. Dr Dunton has been responsible for the approval of approximately 20 New Drug Applications. Dr. Dunton played a key role in the sale of Vylessi® to Cosette Pharmaceuticals for USD $159 million in contingent, sales-based milestones, continuing his track record of fostering advancements in drug development and successful commercialisation efforts. Michele Dilizia – Executive Director & Chief Scientific Officer BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM Co-inventor and qualified medical scientist with a specialisation in medical microbiology and regulatory affairs. Ms Dilizia successfully co-led the research and development of Recce’s suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. FDA. Dr Justin Ward – Executive Director & Principal Quality Chemist BSc (Chem), PhD (Chem), M Pharm, MRACI, CChem A quality control expert who has worked with leading pharmaceutical companies. He previously held a technical role with Pfizer, involving providing data for the regulatory submissions to the FDA and TGA. Dr Ward is bringing Recce’s research and development and manufacturing up to US FDA requirements. Alistair McKeough – Non-Executive Director Mr McKeough is an experienced executive and solicitor. Before being appointed as a non-executive director in 2022, Alistair served as Recce’s company secretary and he has been involved with the company since 2017. Alistair has extensive experience in a variety of private and listed corporations across many sectors, including professional services, technology, financial services, charities, health, biotech, childcare and education. Recent roles include Managing Director of a legal practice specialising in equity capital markets and advice to listed companies and as part of the senior leadership team at share registry, Automic Group. Elusys Therapeutics Recce Pharmaceuticals Limited (ASX:RCE) | Equity Raising Presentation | 14 14 RECCE® 327 Synthetic Anti-Infective Independent Study Undertaken on RECCE® 327 MoA1 Linnaeus Biosciences MoA studies of R327 R327 targets and irreversibly binds to essential bacterial proteins Stage 1 R327 interferes with bacterial cellular metabolism and energy production at or near the cell surface, depleting ATP Stage 3 R327 kills bacteria rapidly without inducing cell lysis Stage 4 R327 is rapidly and irreversibly bactericidal Stage 2 1 – Elucidating the Mechanism of Action of Novel Polymer-based Synthetic Anti-infective Compound RECCE 327 - Abstract Novel mechanism which targets rapid access to and shut down of bacterial energy production (ATP), which results in bacterial death of both active and resting bacteria. 15 R327 kills pathogenic bacteria at a faster rate. R327 Faster Acting Than Existing Antibiotics All compounds used at 2X Minimum Inhibitory Concentration (MIC) R327 kills bacteria in conditions where other antibiotics are ineffective. - Marc Sharp, PhD, Chief Scientific Officer, Linnaeus Biosciences No Prolonged Exposure Needed 16 R327 is faster-acting against bacteria than other antibiotics – works quickly, without prolonged cellular exposure times required of other antibiotics (extended exposures commonly associated with systemic toxicity).* R327 designed to work faster than all existing antibiotics, reinforced by Mo